Neovacs SA (ALNEV) AI Stock Analysis

• Market Cap: €1.72K
• Dividend Yield: N/A
• Average Volume (3M): 1.46M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.55
• Revenue Growth: -45.39%
• EPS Growth: 99.99%
• Country: FR
• Employees: 22
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -5.11
• Shares Outstanding: 476,625
• 10 Day Avg. Volume: 1,456,964
• 30 Day Avg. Volume: 1,459,251
• PEG Ratio: 0.05
• Price to Book (P/B): 9.86
• Price to Sales (P/S): 485.89
• P/FCF Ratio: -48.36
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 37 Underperform
• Price Target: <€0.01 ▼(-10.00% Downside)

Neovacs SA's overall stock score is significantly impacted by its poor financial performance, characterized by declining revenues and negative profit margins. The technical analysis further supports a bearish outlook with oversold conditions. The lack of earnings and dividend yield reflects a weak valuation, contributing to the low overall score.

Positive Factors

Proprietary Kinoid technology

Owning a distinct therapeutic platform (Kinoid) provides a structural competitive advantage across autoimmune indications. If clinical validation continues, the platform enables repeated product opportunities, licensing leverage, and differentiation vs. conventional biologics over the medium term.

Low financial leverage

Minimal debt reduces solvency risk and preserves financing optionality, important for a biotech reliant on development milestones. Lower fixed obligations increase the company's ability to negotiate partnerships or raise equity without constrained cash servicing needs over the next several quarters.

Partnership-driven revenue model

A model focused on collaborations and milestone/royalty streams can provide non-dilutive capital and de-risk late-stage development and commercialization. Durable if the pipeline advances, partnerships can accelerate trials and transfer commercialization burden to larger pharma partners.

Negative Factors

Steep historical revenue decline

Sustained top-line erosion undermines scale economies, reduces bargaining power with partners, and weakens ability to fund R&D internally. Recovering revenue requires successful clinical advancement or deals; absent that, growth prospects remain structurally impaired for months.

Persistent negative operating and free cash flow

Ongoing negative operating and free cash flow erodes reserves and forces reliance on external financing or milestone deals. This structural cash-generation weakness constrains sustained clinical programs and increases dilution or partnership dependency over the medium term.

Chronic unprofitability and thin margins

Persistent negative margins and lack of profitability indicate the business cannot self-sustain operations or scale without material clinical success or external funding. This structural profitability gap raises long-term viability concerns absent transformative pipeline outcomes or major partnerships.

Neovacs SA Business Overview & Revenue Model

Company Description

Neovacs S.A., a biotechnology company, focuses on the development of therapeutic vaccines for the treatment of autoimmune, inflammatory, allergy, and cancer diseases in France. It develops treatments for chronic autoimmune and inflammatory diseases using its proprietary Kinoid technology. The company's product pipeline includes IFNa Kinoid, an anti-interferon alpha vaccine that is in Phase IIb clinical trial for the treatment of systemic lupus erythematosus; Phase IIa clinical trial for the treatment of dermatomyositis; and preclinical stage for the treatment of diabetes. It is also developing VEGF-Kinoid, which is in preclinical stage for the treatment of age-related macular degeneration and solid tumors; and IL-4/IL-13 Kinoid that is in preclinical stage for the treatment of allergies. The company has a collaboration with the Sunnybrook Research Institute for preclinical development of VEGF Kinoid to treat colorectal and ovarian cancer. Neovacs S.A. was founded in 1993 and is based in Paris, France.

How the Company Makes Money

Neovacs generates revenue primarily through the development and commercialization of its therapeutic candidates. The company focuses on securing partnerships and collaborations with larger pharmaceutical companies for the development and marketing of its products, which can include upfront payments, milestone payments based on clinical progress, and royalties on future sales. Additionally, Neovacs may also pursue grant funding and investment to support its research and development activities. The success of its pipeline products and the establishment of strategic alliances are critical to the company's ability to generate revenue.

Neovacs SA Financial Statement Overview

Summary

Neovacs SA is facing significant financial challenges with declining revenues, negative profit margins, and persistent cash flow issues. While the company maintains low leverage, its operational inefficiencies and inability to generate positive cash flow raise concerns about its financial health and long-term viability in the biotechnology industry.

Income Statement

Neovacs SA has faced consistent revenue declines from 2019 to 2024 with a slight uptick in 2024. The company's gross profit margin remains minimal and net income has been persistently negative, indicating a struggle to achieve profitability. EBIT and EBITDA margins are also negative, reflecting significant challenges in operational efficiency and scalability.

Balance Sheet

The company's debt-to-equity ratio is low due to minimal debt levels, suggesting limited leverage risk. However, the continuous decline in stockholders' equity and total assets from 2019 to 2024 is concerning. The equity ratio remains relatively stable, indicating financial structure stability despite operational setbacks.

Cash Flow

Neovacs SA has consistently struggled with negative operating and free cash flow, which raises concerns about liquidity and sustainability. Despite fluctuations, the free cash flow growth rate remains negative, highlighting the company's persistent cash generation issues relative to its expenses.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	366.35K	533.41K	1.11K	22.59K	29.78K
Gross Profit	42.42K	-6.75M	-6.26M	-7.60M	-3.39M
EBITDA	-6.61M	-8.45M	-3.61M	-10.38M	-4.63M
Net Income	-32.91M	-8.74M	-3.55M	-11.84M	-6.14M
Balance Sheet
Total Assets	22.07M	47.53M	49.28M	48.55M	13.49M
Cash, Cash Equivalents and Short-Term Investments	435.45K	887.09K	6.76M	33.09M	10.07M
Total Debt	230.37K	650.59K	1.20M	1.03M	388.36K
Total Liabilities	4.01M	3.71M	5.05M	4.65M	2.50M
Stockholders Equity	18.06M	43.82M	44.23M	43.90M	10.98M
Cash Flow
Free Cash Flow	-3.68M	-2.12M	-4.60M	-10.26M	-5.86M
Operating Cash Flow	-3.60M	-1.91M	-4.45M	-9.91M	-5.65M
Investing Cash Flow	1.45M	-11.08M	-31.56M	-18.81M	-222.71K
Financing Cash Flow	1.70M	6.79M	9.99M	51.75M	14.65M

Neovacs SA Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.01
• 50DMA: Negative
• 100DMA: Negative
• MACD: Negative
• RSI: Positive
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:ALNEV, the sentiment is Negative. The current price of 0.01 is below the 20-day moving average (MA) of 0.02, below the 50-day MA of 0.05, and equal to the 200-day MA of ―, indicating a neutral trend. The MACD of -0.02 indicates Negative momentum. The RSI at 27.04 is Positive, neither overbought nor oversold. The STOCH value of 3.70 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for FR:ALNEV.

Neovacs SA Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ALTHX	48 Neutral	€34.40M	-7.23	―	―	―	10.30%
ALTME	47 Neutral	€6.78M	-1.48	-917.95%	―	―	―
ALBPS	42 Neutral	€2.66M	-0.08	―	―	―	―
ALNEV	37 Underperform	€1.72K	―	―	―	-45.39%	99.99%